Volgen
Alessandra Ferrario
Alessandra Ferrario
Harvard Medical School and Harvard Pilgrim Health Care Institute
Geverifieerd e-mailadres voor harvardpilgrim.org - Homepage
Titel
Geciteerd door
Geciteerd door
Jaar
Challenges in diabetes management in Indonesia: a literature review
P Soewondo, A Ferrario, DL Tahapary
Globalization and health 9, 1-17, 2013
3012013
Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden
A Ferrario, P Kanavos
Social science & medicine 124, 39-47, 2015
1932015
How can pricing and reimbursement policies improve affordable access to medicines? Lessons learned from European countries
S Vogler, V Paris, A Ferrario, VJ Wirtz, K de Joncheere, P Schneider, ...
Applied health economics and health policy 15, 307-321, 2017
1772017
The economic burden of diabetes in India: a review of the literature
CAK Yesudian, M Grepstad, E Visintin, A Ferrario
Globalization and health 10, 1-18, 2014
1722014
Managed entry agreements for pharmaceuticals: the European experience
A Ferrario, P Kanavos
EMINet, 2013
1692013
Epidemiology, management, complications and costs associated with type 2 diabetes in Brazil: a comprehensive literature review
AD Bertoldi, P Kanavos, GVA França, A Carraro, CAO Tejada, PC Hallal, ...
Globalization and health 9, 1-12, 2013
1652013
The implementation of managed entry agreements in Central and Eastern Europe: findings and implications
A Ferrario, D Arāja, T Bochenek, T Čatić, D Dankó, M Dimitrova, J Fürst, ...
Pharmacoeconomics 35, 1271-1285, 2017
1592017
Barriers for access to new medicines: searching for the balance between rising costs and limited budgets
B Godman, A Bucsics, P Vella Bonanno, W Oortwijn, A Ferrario, A Kurdi, ...
Frontiers in Public Health 6, 419528, 2018
1512018
Diabetes management in Thailand: a literature review of the burden, costs, and outcomes
C Deerochanawong, A Ferrario
Globalization and Health 9, 1-18, 2013
1422013
Personalizing health care: feasibility and future implications
B Godman, AE Finlayson, PK Cheema, E Zebedin-Brandl, ...
BMC medicine 11, 1-23, 2013
1292013
Higher US branded drug prices and spending compared to other countries may stem partly from quick uptake of new drugs
P Kanavos, A Ferrario, S Vandoros, GF Anderson
Health affairs 32 (4), 753-761, 2013
1202013
Dabigatran–a case history demonstrating the need for comprehensive approaches to optimize the use of new drugs
RE Malmström, BB Godman, E Diogene, C Baumgärtel, M Bennie, ...
Frontiers in pharmacology 4, 39, 2013
1182013
Assessing adherence to antihypertensive therapy in primary health care in Namibia: findings and implications
MM Nashilongo, B Singu, F Kalemeera, M Mubita, E Naikaku, A Baker, ...
Cardiovascular drugs and therapy 31, 565-578, 2017
972017
Managing risk and uncertainty in health technology introduction: the role of managed entry agreements
P Kanavos, A Ferrario, G Tafuri, P Siviero
Global Policy 8, 84-92, 2017
722017
Challenges in diabetes mellitus type 2 management in Nepal: a literature review
B Gyawali, A Ferrario, E van Teijlingen, P Kallestrup
Global health action 9 (1), 31704, 2016
622016
Diabetes in Algeria and challenges for health policy: a literature review of prevalence, cost, management and outcomes of diabetes and its complications
L Lamri, E Gripiotis, A Ferrario
Globalization and health 10, 1-14, 2014
542014
Drug promotional activities in Nigeria: impact on the prescribing patterns and practices of medical practitioners and the implications
JO Fadare, KA Oshikoya, OO Ogunleye, OO Desalu, A Ferrario, ...
Hospital practice 46 (2), 77-87, 2018
452018
Proposal for a regulation on health technology assessment in Europe–opinions of policy makers, payers and academics from the field of HTA
P Vella Bonanno, A Bucsics, S Simoens, AP Martin, W Oortwijn, ...
Expert review of pharmacoeconomics & outcomes research 19 (3), 251-261, 2019
442019
Strategies to achieve fairer prices for generic and biosimilar medicines
A Ferrario, G Dedet, T Humbert, S Vogler, F Suleman, HB Pedersen
bmj 368, 2020
402020
Global access to quality-assured medical products: the Oxford statement and call to action
PN Newton, KC Bond, P Newton, K Bond, V Abiola, K Ade-Abolade, ...
The Lancet Global Health 7 (12), e1609-e1611, 2019
332019
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20